CSL, Talecris Call Off $3.1B Deal Amid FTC Pressure
By Brendan Pierson ( June 8, 2009, 12:00 AM EDT) -- CSL Ltd. has called off its proposed $3.1 billion acquisition of rival Talecris Biotherapeutics in the face of allegations by the Federal Trade Commission that the deal would have reduced competition in the U.S. market for plasma-derivative protein therapies....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.